| 臺大學術典藏 |
2021-03-10T02:36:31Z |
A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women
|
Tsai M.-S.;Chang S.-H.;Kuo W.-H.;Kuo C.-H.;Li S.-Y.;Wang M.-Y.;Chang D.-Y.;Yen-Shen Lu;Huang C.-S.;Cheng A.-L.;Lin C.-H.;Chen P.-C.; Tsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; YEN-SHEN LU; Huang C.-S.; Cheng A.-L.; Lin C.-H.; Chen P.-C. |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2018 |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W; Yeh D.-C; Chao T.-Y; Lin C.-H; Chow L.W.-C; Chang D.-Y; Hsieh Y.-Y; Huang S.-M; Cheng A.-L; YEN-SHEN LU; Taiwan Breast Cancer Consortium; Chen T.W.-W;Yeh D.-C;Chao T.-Y;Lin C.-H;Chow L.W.-C;Chang D.-Y;Hsieh Y.-Y;Huang S.-M;Cheng A.-L;Yen-Shen Lu;Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-03T10:26:44Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
Yen-Shen Lu; Lee, Keun Seok; Chao, Tsu Yi; Tseng, Ling Ming; Chitapanarux, Imjai; Chen, Shin Cheh; Liu, Chien Ting; Sohn, Joohyuk; Kim, Jee Hyun; Chang, Yuan Ching; Yang, Youngsen; Shotelersuk, Kanjana; Jung, Kyung Hae; Valenti, Roberta; Slader, Cassandra; Gao, Melissa; Park, Yeon Hee |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
YEN-SHEN LU; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. |
| 臺大學術典藏 |
2021-02-02T09:21:43Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid, Peter; Sablin, Marie Paule; Bergh, Jonas; Im, Seock Ah; Yen-Shen Lu; Martínez, Noelia; Neven, Patrick; Lee, Keun Seok; Morales, Serafín; Pérez-Fidalgo, J. Alejandro; Adamson, Douglas; Gonçalves, Anthony; Prat, Aleix; Jerusalem, Guy; Schlieker, Laura; Espadero, Rosa Maria; Bogenrieder, Thomas; Huang, Dennis Chin Lun; Crown, John; Cortés, Javier |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:07Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Yen-Shen Lu;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Yang C.-H.; Lin C.-C; Cheng A.-L; Hsu C.-H; YEN-SHEN LU; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:51:53Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F; Lin C.-H; Kuo C.-H; Chen W.-W; Yeh D.-C; Liao H.-W; Huang S.-M; Cheng A.-L; YEN-SHEN LU; Wu P.-F;Lin C.-H;Kuo C.-H;Chen W.-W;Yeh D.-C;Liao H.-W;Huang S.-M;Cheng A.-L;Yen-Shen Lu |
| 臺大學術典藏 |
2020-05-25T06:51:49Z |
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
|
Chen B.-B;Yen-Shen Lu;Lin C.-H;Chen W.-W;Wu P.-F;Hsu C.-Y;Yu C.-W;Wei S.-Y;Cheng A.-L;Shih T.T.-F.; Chen B.-B; YEN-SHEN LU; Lin C.-H; Chen W.-W; Wu P.-F; Hsu C.-Y; Yu C.-W; Wei S.-Y; Cheng A.-L; Shih T.T.-F. |
| 臺大學術典藏 |
2020-05-25T06:51:46Z |
Adiposity, inflammation, and breast cancer pathogenesis in Asian Women
|
Iyengar N.M;Chen I.-C;Zhou X.K;Giri D.D;Falcone D.J;Winston L.A;Wang H;Williams S;Yen-Shen Lu;Hsueh T.-H;Cheng A.-L;Hudis C.A;Lin C.-H;Dannenberg A.J.; Iyengar N.M; Chen I.-C; Zhou X.K; Giri D.D; Falcone D.J; Winston L.A; Wang H; Williams S; YEN-SHEN LU; Hsueh T.-H; Cheng A.-L; Hudis C.A; Lin C.-H; Dannenberg A.J. |
| 臺大學術典藏 |
2020-05-25T06:51:45Z |
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
|
Ciruelos E.M; Rubovszky G; Campone M; Loibl S; Rugo H.S; Iwata H; Conte P; Mayer I.A; Kaufman B; Yamashita T; YEN-SHEN LU; Inoue K; Takahashi M; P?pai Z; Longin A.-S; Mills D; Wilke C; Hirawat S; Juric D.; Andr? F; Andr? F;Ciruelos E.M;Rubovszky G;Campone M;Loibl S;Rugo H.S;Iwata H;Conte P;Mayer I.A;Kaufman B;Yamashita T;Yen-Shen Lu;Inoue K;Takahashi M;P?Pai Z;Longin A.-S;Mills D;Wilke C;Hirawat S;Juric D. |
| 臺大學術典藏 |
2020-05-25T06:51:43Z |
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
|
Andr? F;Ciruelos E;Rubovszky G;Campone M;Loibl S;Rugo H.S;Iwata H;Conte P;Mayer I.A;Kaufman B;Yamashita T;Yen-Shen Lu;Inoue K;Takahashi M;P?Pai Z;Longin A.-S;Mills D;Wilke C;Hirawat S;Juric D.; Andr? F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo H.S; Iwata H; Conte P; Mayer I.A; Kaufman B; Yamashita T; YEN-SHEN LU; Inoue K; Takahashi M; P?pai Z; Longin A.-S; Mills D; Wilke C; Hirawat S; Juric D. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2�Vnegative advanced breast cancer: final overall survival results from SOLAR-1
|
Andr? F.; Ciruelos E.M.; Juric D.; Loibl S.; Campone M.; Mayer I.A.; Rubovszky G.; Yamashita T.; Kaufman B.; YEN-SHEN LU; Inoue K.; P?pai Z.; Takahashi M.; Ghaznawi F.; Mills D.; Kaper M.; Miller M.; Conte P.F.; Iwata H.; Rugo H.S. |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo, Winnie; Yap, Yoon Sim; Park, Yeon Hee; Tamura, Kenji; Li, Huiping; Cheng, Rebecca |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo W.; Yap Y.-S.; Park Y.H.; Tamura K.; Li H.; Cheng R. |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai, Ming Shen; Feng, Yin Hsun; Chen, Shang Wen; Masuda, Norikazu; Yau, Thomas; Chen, Shou Tung; YEN-SHEN LU; Yap, Yoon Sim; Ang, Peter C.S.; Chu, Sung Chao; Kwong, Ava; Lee, Keun Seok; Ow, Samuel; Kim, Sung Bae; Lin, Johnson; Chung, Hyun Cheol; Ngan, Roger; Kok, Victor C.; Rau, Kun Ming; Sangai, Takafumi; Ng, Ting Ying; Tseng, Ling Ming; Bryce, Richard; Bebchuk, Judith; Chen, Mei Chieh; Hou, Ming Feng |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI
|
Tseng W.-Y.I.;Yen-Shen Lu;Chen J.-H;Liu Y.-J;Huang C.-S;Chang Y.-C; Chang Y.-C; Huang C.-S; Liu Y.-J; Chen J.-H; YEN-SHEN LU; Tseng W.-Y.I. |
| 臺大學術典藏 |
2021-08-15T00:08:34Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen, I. Chun; Hu, Fu Chang; CHING-HUNG LIN; Huang, Shu Min; Chang, Dwan Ying; ANN-LII CHENG; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2018 |
Association of pregnancy and mortality in women diagnosed with breast cancer: A Nationwide Population Based Study in Taiwan
|
Chuang S.-C;Lin C.-H;Yen-Shen Lu;Hsiung C.A.; Chuang S.-C; Lin C.-H; YEN-SHEN LU; Hsiung C.A. |
| 臺大學術典藏 |
2020-05-25T06:51:52Z |
Associations between medical conditions and breast cancer risk in asians: A nationwide population-based study in Taiwan
|
Chuang S.-C;Wu G.-J;Yen-Shen Lu;Lin C.-H;Hsiung C.A.; Chuang S.-C; Wu G.-J; YEN-SHEN LU; Lin C.-H; Hsiung C.A. |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models (Scientific Reports, (2019), 9, 1, (10898), 10.1038/s41598-019-45319-4)
|
Kuo C.-T.; Chen C.-L.; Li C.-C.; Huang G.-S.; Ma W.-Y.; Hsu W.-F.; Lin C.-H.; YEN-SHEN LU; Wo A.M. |
